《新股消息》據報奈雪的茶目標6月至7月上市 估值或達400億人幣
內媒引述消息人士指,內地茶飲品牌「奈雪的茶」目標於5月底或者6月初通過上市聆訊,並於6月至7月完成招股掛牌,計劃發售約15%新股,預期估值或將達到350億至400億元人民幣。
消息人士指,由於此前未有茶飲公司上市,因此監管機構審查較嚴格,並透露奈雪的茶上星期已就聯交所最新一輪問詢提交回覆。
昨日有市場傳聞指,奈雪的茶已通過上市聆訊,公司隨後否認,強調正按計劃推進IPO事宜。此前有傳奈雪的茶計劃集資約5億至6億美元,奈雪的茶創始人彭心出席活動時表示,上市並非因為缺錢,而是希望令公司經營更長久、更開放透明。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.